On Thursday, August 21, the Apple Health (Medicaid) customer service phone lines will be down from 11:30 to 3:15 p.m. We apologize for any inconvenience. View other ways to contact Apple Health.
The Health Care Authority (HCA) is reopening applications from small providers to join the long-acting injectable (LAI) buprenorphine funding program.
The deadline to submit applications is end of day October 31, 2025.
Small providers interested in providing LAI buprenorphine to uninsured patients should apply for these funds by:
The LAI Buprenorphine Funding Program is a ship to/bill to arrangement for small providers to stock LAI buprenorphine in their clinic. When working with an uninsured patient with an opioid use disorder, the provider can treat that individual right then, rather than expecting the patient to return to the clinic once the medication arrives. HCA is covering the cost of the medications with funds from the opioid abatement settlement. Small providers are defined as a clinic with 5 or fewer licensed prescribers that prescribe Sublocade or Brixadi, and are not owned or operated by a hospital or carceral facility.
This program ends on June 30, 2027, or when funding is exhausted. The directive has changed from the 2024 fiscal year to only cover uninsured patients.
Find out more about this program and the application process in the frequently asked questions (FAQ).
